Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microcytosis Is a Risk Marker of Cancer in Primary Care

By LabMedica International staff writers
Posted on 20 May 2020
Microcytosis is a term used to describe red blood cells that are smaller than normal. More...
Anemia is when there are low numbers of properly functioning red blood cells in the body. In microcytic anemia, the body has fewer red blood cells than normal and those red blood cells it does have are also too small.

In anemia of chronic disease, about one-fourth to one-third of these types of anemia are classified as microcytic. Some of the conditions that can cause this type of anemia include: kidney disease, certain cancers, such as Hodgkin's disease, non-Hodgkin's lymphoma, and breast cancer.

A team of medical scientists from the University of Exeter Medical School (Exeter, UK) examined cancer incidence in a cohort of patients with microcytosis, with and without accompanying anemia. The cohort of 12,289 patents were aged ≥40 years using UK primary care electronic patient records. The 1-year cancer incidence was compared between cohorts of patients with a mean red cell volume of <85 femtolitres (fL) (low) or 85–101 fL (normal). Further analyses examined sex, age group, cancer site, and hemoglobin values.

The investigators reported that of 12,289 patients with microcytosis, 497 (4.0%) had a new cancer diagnosis within one year, compared with 1,465 of 73,150 (2.0%), without microcytosis. In males, 298 out of 4,800 with microcytosis were diagnosed with cancer (6.2%) compared with 940 out of 34,653 without (2.7%). In females with microcytosis, 199 out of 7,489 were diagnosed with cancer (2.7%), compared with 525 out of 38 497 without (1.4%). In patients with microcytosis but normal hemoglobin, 86 out of 2,637 males (3.3%), and 101 out of 5,055 females (2.0%) were diagnosed with cancer.

Willie Hamilton, MD, a Professor of Primary Care Diagnostics who oversaw the study, said, “Overall, the risk of cancer in patients with microcytosis was still low, however our study indicates a need to investigate cancer. In two patients with cancer out of three the possibility of cancer is fairly easy to identify. For the other third, symptoms are often vague, and don't clearly point to cancer. For these patients physicians have to use more subtle clues to recognize that cancer may be present. Small red cells have long been recognized with colon cancer, but this study shows that they are a much broader clue, alerting the doctor to the small possibility of one of several possible cancers.”

The authors concluded that microcytosis is a predictor of underlying cancer even if hemoglobin is normal. Although a benign explanation is more likely, clinicians in primary care should consider simple testing for cancer on encountering unexplained microcytosis, particularly in males. The study was published on May 4, 2020 in the British Journal of General Practice.

Related Links:
University of Exeter Medical School


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.